The City’s attention has been diverted from gilt yields to a rather more visceral drama: the case of Dr. Cyriac Abby Philips, known to his 400,000 followers as The Liver Doc. His aggressive takedowns of dubious medical claims on social media have made him a hero to some and a villain to others. But the real story lies not in his viral fame but in the ethical implications that are now washing up on British shores.
Philips, a hepatologist based in Kerala, has built a reputation by exposing quackery, particularly alternative medicine practitioners who promise miracle cures for liver disease. His methods are blunt. He names, shames, and often uses language that would make a junior trader blush. His supporters argue that such force is necessary to combat the thousands of charlatans who profit from desperate patients. His detractors, including some within the medical establishment, claim his approach undermines trust in the profession and borders on harassment.
Now, the debate has crossed the Indian Ocean. The UK’s General Medical Council (GMC) is facing renewed scrutiny over how it polices online conduct by doctors. The case of Philips raises uncomfortable questions. Should a doctor be censured for being rude if the end result saves lives? Or must the profession maintain a decorum that, in the age of viral misinformation, seems increasingly archaic?
This is not an abstract philosophical debate. It has real economic consequences. The UK’s private healthcare market is already under pressure from capital flight, as high net worth individuals seek jurisdictions with more predictable regulatory environments. If the GMC is seen as either too draconian or too lax, it could affect the reputation of British medicine. And reputation, as any fund manager knows, is a fragile asset. Talk to a broker in Mayfair and they will tell you that trust in institutions is the bedrock of market stability. The moment that trust erodes, spreads widen, premiums rise, and capital looks for the exit.
The parallels with financial regulation are striking. When the Financial Conduct Authority fined banks for mis-selling, it was lauded for cleaning up the industry. But when it pursued bankers for minor infractions, critics said it was stifling innovation. The GMC now faces the same balancing act. It must decide whether a doctor’s online aggression is a breach of professional standards or a necessary defence against a public health crisis.
Let me be clear: I have no sympathy for charlatans. The market for fake cures is a tax on the desperate. If Dr. Philips reduces that market, he is performing a valuable public service. But the method matters. In finance, we have insider trading rules that are designed to maintain market integrity, even when the information being traded could make someone a fortune. The same principle applies here. The end does not always justify the means.
Consider the macro picture. The UK’s National Health Service is already struggling with a budget that inflates faster than the waiting lists. If public trust in doctors erodes, more patients will seek expensive private alternatives, further straining the fiscal system. The Treasury takes note of these things. The Chancellor may not tweet about liver doctors, but he cares about the bottom line.
Meanwhile, the Government’s own fiscal responsibility is in question. The latest borrowing figures show that the public finances are on an unsustainable path. The new chancellor, Rachel Reeves, has promised to be ‘iron chancellor’ but the markets are watching. Gilt yields have been edging up, reflecting the risk premium demanded by investors who worry about Labour’s spending plans. The case of Dr. Philips may seem a sideshow, but it is indicative of a broader malaise: a loss of faith in institutions that enforce standards. Whether it is the GMC or the Treasury, credibility is everything.
So as the GMC deliberates on its guidance for doctors online, it might consider the parallels with monetary policy. The Bank of England does not adjust interest rates based on one data point. It looks at the trend. Similarly, the GMC should not overreact to one controversial doctor. But it must ensure that the herd of doctors posting online does not stampede towards a cliff.
For now, the City waits. The market volatility we are seeing may have more to do with central bank policy than medical ethics. But make no mistake: the case of The Liver Doc is a stress test for professional regulation. The outcome will be priced in, one way or another.
